Acute Intermittent Porphyria News and Research

RSS
New acute porphyria treatment shows promising results in clinical study

New acute porphyria treatment shows promising results in clinical study

New pre-clinical research shows utility of mRNA platform to treat rare metabolic disorders

New pre-clinical research shows utility of mRNA platform to treat rare metabolic disorders

Alnylam announces positive results from Phase 3 Study of givosiran for treating acute hepatic porphyria

Alnylam announces positive results from Phase 3 Study of givosiran for treating acute hepatic porphyria

Wrecked and retching: Obscure vomiting illness linked to long-term pot use

Wrecked and retching: Obscure vomiting illness linked to long-term pot use

New gene therapy for Acute Intermittent Porphyria

New gene therapy for Acute Intermittent Porphyria

Alnylam advances Development Candidate for ALN-AS1 for treatment of hepatic porphyrias

Alnylam advances Development Candidate for ALN-AS1 for treatment of hepatic porphyrias

Alnylam reports pre-clinical data from ALN-AS1 program for treatment of AIP

Alnylam reports pre-clinical data from ALN-AS1 program for treatment of AIP

uniQure commences acute intermittent porphyria Phase I clinical trial

uniQure commences acute intermittent porphyria Phase I clinical trial

uniQure receives positive recommendation from EMA CHMP for Glybera

uniQure receives positive recommendation from EMA CHMP for Glybera

AMT total net loss decreases 7% to € 8.7 million for first half year of 2011

AMT total net loss decreases 7% to € 8.7 million for first half year of 2011

AMT 2010 total net income increases to EUR 1.4 million

AMT 2010 total net income increases to EUR 1.4 million

Digna Biotech, CIMA receive EU grant for development of gene therapy product for Acute Intermittent Porphyria

Digna Biotech, CIMA receive EU grant for development of gene therapy product for Acute Intermittent Porphyria

EU grants 3.3 million to AMP for gene therapy development against AIP

EU grants 3.3 million to AMP for gene therapy development against AIP

AMT announces full year 2009 results; reports modest decrease in operating expenses

AMT announces full year 2009 results; reports modest decrease in operating expenses

Amsterdam Molecular Therapeutics provides third-quarter 2009 business updates

Amsterdam Molecular Therapeutics provides third-quarter 2009 business updates

Treatment for acute intermittent porphyria

Treatment for acute intermittent porphyria